We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including the MOPEAD initiative. MOPEAD (Models of Patient Engagement for Alzheimer’s disease), aims to deliver a step-change in AD patient engagement strategies and a paradigm shift from late-stage diagnosis […]
Tim J von Oertzen (Kepler Universitätsklinikum, Linz, Austria) describes interim findings that highlight the promising utility of multiple subtraction ictal SPECT coregistered to MRI (SISCOM) to guide presurgical evaluation of patients with drug-refractory epilepsy. Questions 1. What are the major challenges in the presurgical evaluation of candidates with drug-refractory epilepsy? (0:05) 2. Could you give […]
Our editorial board member and EAN Secretary General, Marianne de Visser (Academic Medical Centre, Amsterdam, The Netherlands), shares her expert insight into pregnancy and neuromuscular disorders. Questions 1. How does pregnancy affect the symptoms of neuromuscular disorders? (0:05) 2. What are the implications of neuromuscular disorders and their treatments for the development of the fetus […]
As a coordinating member of the EANcore COVID-19 initiative, Elena Moro (Centre Hospitalier Universitaire de Grenoble, France), discusses the importance of the EAN’s recently completed survey of neurological symptoms in patients with COVID-19. Questions 1. Could you give us an overview of the EAN Survey of Neurological Symptoms in COVID-19 Patients? (0:05) 2. How will […]
EAN Treasurer, Elena Moro (Centre Hospitalier Universitaire de Grenoble, France), kindly took the time to share with us her expert perspective on the neurological implications of COVID-19 in Europe. Questions 1. What are the neurological implications of COVID-19 in Europe? (0:05) 2. What are the major risks posed by COVID-19 in patients with neurological illness? […]
EAN Acting President, Prof. Claudio Bassetti (Inselspital, Bern University Hospital, University of Bern, Switzerland), talks to us about the recently launched EANcore COVID-19 initiatives, providing valuable resources in the ongoing global crisis. Questions 1. What are the biggest challenges that neurologists face during the CoVID-19 pandemic? (0:05) 2. What are the aims of the EANcore […]
Heinz Reichmann (Universitätsklinikum Carl Gustav Carus, Dresden, Germany) shares key findings and expert insights into the OPTIPARK study, a prospective, open-label, uncontrolled, single-group, multi-centre trial in patients with Parkinson’s disease and wearing-off motor fluctuations (ClinicalTrials.gov Identifier: NCT02847442). Questions 1. What were the aims and design of the OPTIPARK study? (0:05) 2. What were the efficacy […]
We were fortunate to have the opportunity to catch up with European editorial board member, Heinz Reichmann (Universitätsklinikum Carl Gustav Carus, Dresden, Germany), who spoke to us about unmet needs in the treatment of Parkinson’s disease and clinical evidence supporting the efficacy and safety of catechol-O-methyltransferase inhibition as a means to prolong the effects of […]
Angelo Antonini (University of Padova, Veneto, Italy), one of our valued European editorial board members, discusses impulse control disorders in patients with Parkinson’s disease including findings related to these behaviours in the Parkinson’s Disease Real-World Impact Assessment (PRISM) study. Questions 1. What are the major impulse control disorders seen in patients with Parkinson’s disease and […]
Get the latest clinical insights from touchNEUROLOGY